<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527930</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-BR-0703, H-0706-009-209</org_study_id>
    <nct_id>NCT00527930</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer</brief_title>
  <acronym>TORCH</acronym>
  <official_title>Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of oxaliplatin in combination with S-1(SOX) in patients with recurrent or
      metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline and
      taxane
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to find out the efficacy and safety profile of TS-1 with
      oxaliplatin in previously anthracycline and taxane pretreated patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>TTP, OS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To determine the time to progression - To determine the response duration - To determine the overall survival - To determine toxicities - To determine the pharmacogenomic predictor (association study)</measure>
    <time_frame>PFS, OS</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">87</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1 and Eloxatin</intervention_name>
    <description>S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week
Number of Cycles: until progression or unacceptable toxicity</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  M/F age ≥ 18

          -  Metastatic(TxNxM1) or inoperable locally recurrent breast cancer(rT4NxM0) after taxane
             &amp; anthracycline therapy

          -  Measurable disease (RECIST) : A patient with at least one measurable lesion of which
             the diameter is confirmed to be 10mm in spiral CT or multidetector CT (MD CT), or 20
             mm or longer in conventional CT

          -  No prior treatment with S-1, capecitabine, platinum In metastatic setting

          -  Must have received an anthracycline and taxane in adj. or metastatic settings
             (concurrent, sequential, or combined with other drugs)

          -  For taxanes (Paclitaxel (P) / Docetaxel (D))

               1. Must have progressed while or after receiving P or D (Patients who relapse within
                  12 months of completing adjuvant chemotherapy containing an anthracycline and a
                  taxane, do not require prior chemotherapy for metastatic disease)

               2. Only 1 adjuvant regimen permitted (neoadjuvant immediately followed by surgery
                  and immediately followed by adj. is permitted)

          -  For anthracyclines

               1. Progressed while on anthracycline treatment, with or without initial response or

               2. Have received an adequate course of anthracyclines defined as follows:

               1. Adj.: Must have received a standard regimen (doxorubicin ≥ 240 mg/m2 or ≥ 360
                  mg/m2 epirubicin or equivalent)

               2. Metastatic: Must have received a standard regimen(doxorubicin ≥300mg/m2 or
                  equivalent)

          -  Not candidate for Herceptin

          -  ECOG PS ≤ 2

          -  Completion of all prior chemotherapy ≥ 3 wks prior to enrol

          -  Completion of hormonal therapy 2 wks prior to enroll

          -  Resolution of all clinically significant toxic effects (excluding alopecia and sensory
             neuropathies) of any prior surgery or therapy to grade ≤ 1 (NCI CTCAE 3.0), for
             peripheral neuropathy grade ≤ 2 (NCI CTCAE 3.0), or to within the limits listed in the
             specific inclusion/exclusion criteria

          -  A patient with the willingness to comply with the study protocol during the study
             period and capable of complying with it.

          -  Informed consent obtained.

        Exclusion Criteria:

          -  WOCBP(woman of child bearing potential) unwilling to use acceptable method to avoid
             pregnancy

          -  Breast feeding or pregnant women

          -  Patients with Hx of symptomatic brain or leptomeningeal involvement (eligible if
             asymptomatic 2weeks after proper radiation therapy)

          -  ≥grade 3 neuropathy currently

          -  Hx of second malignancy except adequately treated basal or squamous skin ca or CIS of
             cervix. Adequately treated contralateral breast ca with DF &gt;5 yrs prior to this study
             is permitted

          -  MI, unstable angina, CABG, clinically significant arrhythmia within 6 mo

          -  Hx of inflammatory bowel disease or chronic diarrhea,

          -  ANC &lt; 1500, Plt &lt; 100K, Hb &lt;9.0

          -  Ccr &lt; 60 ml/min or creatinine &gt;1.5

          -  Bil &gt; 1.5 x UNL, AST/ALT ≥ 2.5xUNL if hepatic meta + &gt; 5xUNL)

          -  History of hypersensitivity to 5-FU, platinum, or to compounds with similar chemical
             structures

          -  More than 3 prior chemotherapy for metastatic or recurrent disease or prior treatment
             with S-1, capecitabine or any platinum analogs in metastatic setting (5-FU combine
             with other agent in metastatic setting is allowed_ ex) CMF, FAC)

          -  Her2(+) pts who are candidates for Herceptin

          -  prior surgery within 4 week

          -  participate in other clinical trials within 4 week

          -  prior radiation therapy within 2 week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seock-Ah Im, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.kcsg.org/</url>
    <description>Korean Cancer Study Group</description>
  </link>
  <link>
    <url>http://cris.snuh.org</url>
    <description>Seoul National University Hospital Clinical Trial Center</description>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2007</study_first_submitted>
  <study_first_submitted_qc>September 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seock-Ah Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>S1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

